Research ArticleCancer

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

See allHide authors and affiliations

Science Translational Medicine  07 Dec 2016:
Vol. 8, Issue 368, pp. 368ra172
DOI: 10.1126/scitranslmed.aag0976

Log in to view full text

Log in through your institution

Log in through your institution

Navigate This Article